Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Three-Drug showdown aims to end stent pain for kidney stone patients

NCT ID NCT06803030

Symptom relief Sponsor: Bir Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study compares three common drugs—tamsulosin, solifenacin, and mirabegron—to see which one works best for reducing symptoms caused by ureteral stents placed after kidney stone surgery. About 189 adults will take one of the three pills daily and report their symptoms using a questionnaire. The goal is to find the most effective option to improve comfort while the stent is in place.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
tamsulosin, solifenacin, mirabegron
What this could lead to
If successful, this could identify the best drug to reduce pain and urinary symptoms caused by ureteral stents, improving comfort for patients after stone surgery.
What could go wrong
This is a moderate-sized Phase 3 trial, but results may not apply to all stent patients. The drugs have known side effects like dry mouth or dizziness, and the best option may still leave some symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 189 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: • Eligible participants were adult patients (aged 19-80 years) who underwent unilateral retrograde rigid ureteroscopy (URS) or retrograde intrarenal surgery (RIRS) with planned ureteric stent insertion for urinary tract stones Exclusion Criteria: * Concomitant use of a-blockers, anticholinergics, corticosteroids, calcium channel blockers, and analgesics * Undergoing percutaneous nephrolithotomy, open ureteric surgery or laparoscopic ureteric surgery, including ureterolithotomy * Neurogenic bladder, Over Active Bladder (OAB) syndrome, and neurological and psychiatric diseases * Preoperative febrile Urinary Tract Infection (UTI) * Pregnancy or breastfeeding; * A single kidney * Moderate or severe cardiovascular or cerebrovascular disease * Hepatic dysfunction * History of pelvic surgery or irradiation * History of bladder or prostate surgery * Other acute medical conditions (including acute pancreatitis, acute gastroenteritis, musculoskeletal disorders) that might influence the Ureteral Stent Symptom Questionnaire(USSQ) pain score * Allergy to any medication

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ureteral stent-related symptom are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

urolithiasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ureteral stent-related symptom

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • NAMS, Bir Hospital

    RECRUITING

    Kathmandu, Bagmati, 44600, Nepal

More trials for these conditions

Other studies related to the condition(s) this trial covers.